Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells

Zhang,Hui‑Hui; Huang,Bo; Cao,You‑Han; Li ,Qing; Xu,Han‑Feng

doi:10.3892/ol.2017.6853

Role of 5‑Aza‑CdR in mitomycin‑C chemosensitivity of T24 bladder cancer cells

Authors:
- Hui‑Hui Zhang
- Bo Huang
- You‑Han Cao
- Qing Li
- Han‑Feng Xu
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: August 31, 2017 https://doi.org/10.3892/ol.2017.6853
Pages: 5652-5656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapeutic insensitivity is one of key obstacles to effectively treating muscle invasive bladder cancer. 5‑Aza‑2'‑deoxycytidine (5‑Aza‑CdR) has been identified as a tumor suppressive agent in various types of cancer. The aim of the present study was to identify the effects of 5‑Aza‑CdR on the mitomycin‑C (MMC) chemosensitivity of T24 bladder cancer cells and investigate the underlying mechanisms. T24 cells were treated with a combination of MMC and 5‑Aza‑CdR at various concentrations. The rates of proliferation and apoptosis were assessed by an MTT assay and flow cytometry, respectively. The expression of drug resistance‑associated proteins, including P‑glycoprotein (P‑gp) and multidrug resistance‑associated protein 1 (MRP1), and autophagy‑associated proteins, including beclin 1, nucleoporin 62 (p62) and autophagy protein 5 (ATG5) were detected with western blotting. Treatment with 5‑Aza‑CdR significantly promoted the MMC chemosensitivity of T24 cells. The proliferation of T24 cells was significantly inhibited with increasing 5‑Aza‑CdR concentration, whereas apoptosis was significantly increased. This was associated with the decreased expression of P‑gp, MRP1, beclin 1, p62 and ATG5. In conclusion, 5‑Aza‑CdR enhanced MMC chemosensitivity in bladder cancer T24 cells, which may be caused by the suppression of drug resistance‑ and autophagy‑associated proteins.

View Figures

View References

1	Chen Y, Yang Y, Liu L, Wang S, Song H and Liu X: Tumor suppressor in lung cancer-1 is a prognostic predictor for the recurrence and progression of non-muscle-invasive bladder cancer. Urol Int. 96:142–147. 2016. View Article : Google Scholar : PubMed/NCBI
2	Jayaratna IS, Navai N and Dinney CP: Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol. 4:273–282. 2015.PubMed/NCBI
3	Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al: Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016. View Article : Google Scholar : PubMed/NCBI
4	Byun SJ, Kim JH, Oh YK and Kim BH: Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. Radiat Oncol J. 33:294–300. 2015. View Article : Google Scholar : PubMed/NCBI
5	Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S, Li J, Wu F, Zhang H, Zhao Z and Ding S: A Potent chemotherapeutic strategy with Eg5 inhibitor against gemcitabine resistant bladder cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI
6	Vasquez JL, Gehl J and Hermann GG: Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: A potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry. 88:127–133. 2012. View Article : Google Scholar : PubMed/NCBI
7	Gederaas OA, Søgaard CD, Viset T, Bachke S, Bruheim P, Arum CJ and Otterlei M: Increased anticancer efficacy of intravesical mitomycin c therapy when combined with a PCNA targeting peptide. Transl Oncol. 7:812–823. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zhang H, Qi F, Cao Y, Zu X, Chen M, Li Z and Qi L: 5-Aza-2′-deoxycytidine enhances maspin expression and inhibits proliferation, migration, and invasion of the bladder cancer T24 cell line. Cancer Biother Radiopharm. 28:343–350. 2013. View Article : Google Scholar : PubMed/NCBI
9	Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol. 8:67–113. 1992. View Article : Google Scholar : PubMed/NCBI
10	Sedláková I, Laco J, Caltová K, Červinka M, Tošner J, Řezáč A and Špaček J: Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer. 25:236–243. 2015. View Article : Google Scholar : PubMed/NCBI
11	Kovalev AA, Tsvetaeva DA and Grudinskaja TV: Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol. 35:287–290. 2013.PubMed/NCBI
12	Roundhill E and Burchill S: Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT. Br J Cancer. 109:195–206. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yang X, Shen J, Gao Y, Feng Y, Guan Y, Zhang Z, Mankin H, Hornicek FJ and Duan Z: Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. Int J Cancer. 137:2029–2039. 2015. View Article : Google Scholar : PubMed/NCBI
14	Katagiri H, Nakayama K, Razia S, Nakamura K, Sato E, Ishibashi T, Ishikawa M, Iida K, Ishikawa N, Otsuki Y, et al: Loss of autophagy-related protein Beclin 1 may define poor prognosis in ovarian clear cell carcinomas. Int J Oncol. 47:2037–2044. 2015. View Article : Google Scholar : PubMed/NCBI
15	Bartsch G, Jennewein L, Harter PN, Antonietti P, Blaheta RA, Kvasnicka HM, Kögel D, Haferkamp A, Mittelbronn M and Mani J: Autophagy-associated proteins BAG3 and p62 in testicular cancer. Oncol Rep. 35:1629–1635. 2016. View Article : Google Scholar : PubMed/NCBI
16	Ge J and Chen Z, Huang J, Chen J, Yuan W, Deng Z and Chen Z: Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer. PLoS One. 9:e1102932014. View Article : Google Scholar : PubMed/NCBI
17	Levine B: Cell biology: Autophagy and cancer. Nature. 446:745–747. 2007. View Article : Google Scholar : PubMed/NCBI
18	Yang Z, Zhao T, Liu H and Zhang L: Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep. 6:193832016. View Article : Google Scholar : PubMed/NCBI
19	Chang SJ, Ou-Yang F, Tu HP, Lin CH, Huang SH, Kostoro J, Hou MF, Chai CY and Kwan AL: Decreased expression of autophagy protein LC3 and stemness (CD44⁺/CD24⁻/low) indicate poor prognosis in triple-negative breast cancer. Hum Pathol. 48:48–55. 2016. View Article : Google Scholar : PubMed/NCBI
20	Masuda GO, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K, et al: Clinicopathological correlations of autophagy-related proteins LC3, Beclin 1 and p62 in gastric cancer. Anticancer Res. 36:129–136. 2016.PubMed/NCBI
21	Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y and Fan Y: Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Tumour Biol. 37:7371–7381. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, Bai YY, Cheng YZ, Nan KJ and Liang X: Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther. 9:6421–6431. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yang MC, Wang HC, Hou YC, Tung HL, Chiu TJ and Shan YS: Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Mol Cancer. 14:1792015. View Article : Google Scholar : PubMed/NCBI